Risks
3 risks
Risk Intelligence
Geopolitical disruptions and input cost inflation
View Risks →Vimta Labs Ltd — Q4 FY26
Vimta Labs delivered a strong Q4 FY26 with revenue of ₹112 crore (+16.6% YoY) and EBITDA of ₹42.1 crore (+21.5% YoY), driven by robust performance in pharma and food testing.
bullish
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Vimta Labs delivered a strong Q4 FY26 with revenue of ₹112 crore (+16.6% YoY) and EBITDA of ₹42.1 crore (+21.5% YoY), driven by robust performance in pharma and food testing. EBITDA margin expanded to 37.6% (+150 bps YoY), among the best in the industry. The company entered biologics CRD services, with infrastructure ready and client discussions underway. Management targets maintaining 20-25% revenue CAGR and sustaining margins around 35%, though near-term headwinds from geopolitical tensions and input cost inflation pose risks. The balance sheet remains net debt-free with ₹65 crore cash. Key risk: any escalation in global trade disruptions could impact client spending and delay growth.
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Export Revenue Share
38%
flat
Export revenue remained at 38% of total revenue in Q4 FY26.
Full Year Revenue
₹463 million
+19.5% YoY
FY26 total income was ₹463 million, up 19.5% from ₹348.2 million in FY25.
Full Year EBITDA Margin
35.8%
-30bps YoY
FY26 EBITDA margin was 35.8%, slightly down from 36.1% in FY25.
Cash and Equivalents
₹650 million
flat
Company maintains a net debt-free balance sheet with cash and equivalents of ₹650 million.
Fast read
Guidance and risk preview
Management targets maintaining historical CAGR of 20-25% annually, aiming for ₹500 crore revenue run-rate.
The Iran-US war has increased consumable costs and lead times, impacting margins and operations.
View Risks →